BACKGROUND: Preclinical data suggests that VEGF and COX-2 are potentially important mediators in the pathogenesis of small cell lung cancer (SCLC). Little is known about the frequency of tumor expression of VEGF and COX-2 in SCLC or the prognostic significance of this expression. MATERIALS AND METHODS: Clinical records from 54 cases of SCLC were reviewed. Immunohistochemical stains for VEGF and COX-2 were performed on all tumor specimens. RESULTS: Tumor VEGF expression was detected in 43 cases (81%) and COX-2 expression in 11 (20%). No significant association between VEGF or COX-2 expression and survival was observed. CONCLUSION: This is the first study to assess the frequency and clinical significance of tumor VEGF and COX-2 expression in a large group of patients with SCLC. In this cohort, neither VEGF nor COX-2 expression impacted survival. The frequency of VEGF expression suggests that it merits further investigation as a therapeutic target in SCLC.
BACKGROUND: Preclinical data suggests that VEGF and COX-2 are potentially important mediators in the pathogenesis of small cell lung cancer (SCLC). Little is known about the frequency of tumor expression of VEGF and COX-2 in SCLC or the prognostic significance of this expression. MATERIALS AND METHODS: Clinical records from 54 cases of SCLC were reviewed. Immunohistochemical stains for VEGF and COX-2 were performed on all tumor specimens. RESULTS:TumorVEGF expression was detected in 43 cases (81%) and COX-2 expression in 11 (20%). No significant association between VEGF or COX-2 expression and survival was observed. CONCLUSION: This is the first study to assess the frequency and clinical significance of tumorVEGF and COX-2 expression in a large group of patients with SCLC. In this cohort, neither VEGF nor COX-2 expression impacted survival. The frequency of VEGF expression suggests that it merits further investigation as a therapeutic target in SCLC.
Authors: Neal E Ready; Herbert H Pang; Lin Gu; Gregory A Otterson; Sachdev P Thomas; Antonius A Miller; Maria Baggstrom; Gregory A Masters; Stephen L Graziano; Jeffrey Crawford; Jeffrey Bogart; Everett E Vokes Journal: J Clin Oncol Date: 2015-03-02 Impact factor: 44.544
Authors: F Koinis; S Agelaki; V Karavassilis; N Kentepozidis; E Samantas; S Peroukidis; P Katsaounis; E Hartabilas; I I Varthalitis; I Messaritakis; G Fountzilas; V Georgoulias; A Kotsakis Journal: Br J Cancer Date: 2017-05-16 Impact factor: 7.640